| PCR-RDB cotesting | Cervista® cotesting | P-value |
---|---|---|---|
Arm 1 (n = 3272) | |||
 Sensitivity | 93.3% (87.7–98.9%) | 80.6% (71.4–89.7%) | 0.019 |
 Specificity | 91.6% (90.7–92.6%) | 93.4% (92.6–94.3%) | 0.007 |
 PPV | 20.8% (18.8–23.2%) | 21.6% (19.9–23.9%) | 0.873 |
 NPV | 99.8% (99.8%–100.0%) | 99.5% (99.3–99.7%) | 0.031 |
 PLR | 11.4 (9.8–12.7) | 12.6 (10.3–14.6) | / |
 NLR | 0.07 (0.03–0.17) | 0.21 (0.13–0.33) | / |
 No. of cases identified at first round screening | 70 | 58 | / |
 No. of cases identified at 1-year follow-up | 5 | 14 | / |
 No. of cases identified at sequent follow-up | 3 | 5 | / |
 No. of colposcopies to identified 1 case at first round | 4.81 | 4.62 | / |
 Cost per 1000 screened women at first round screeninga | $ 52,292 (¥ 366,044) | $ 51,238 (¥ 358,666) | / |
 Cost per 1000 screened women at 1-year follow-up | $ 5640 (¥ 39,480) | $ 6684 (¥ 46,788) | / |
 Total cost per 1000 screened women per round | $ 57,932 (¥ 405,524) | $ 57,922 (¥ 405,454) | / |
Cost per each identified CIN2+ women per round | $ 2527 (Â¥ 17,689) | $ 2632 (Â¥ 18,424) | / |
Arm 2 (n = 11,638) vs. Arm 3 (n = 9909)b | |||
 Sensitivity | 93.2% (90.6–95.7) | 80.7% (76.2–85.2) | < 0.001 |
 Specificity | 93.0% (92.5–93.5) | 95.7% (95.3–96.1) | < 0.001 |
 PPV | 31.1% (28.4–33.7) | 36.0% (32.3–39.7) | 0.037 |
 NPV | 99.8% (99.7–99.9) | 99.4% (99.2–99.6) | < 0.001 |
 PLR | 13.8 (12.4–14.3) | 19.2 (16.7–20.8) | / |
 NLR | 0.07 (0.05–0.11) | 0.20 (0.16–0.26) | / |
 No. of cases identified at first round screening | 355 | 234 | / |
 No. of cases identified at 1-year follow-up | 26 | 56 | / |
 No. of cases identified at sequent follow-up | 20 | 12 | / |
 No. of colposcopies to identified 1 case at first round screening | 3.22 | 2.78 | / |
 Cost per 1000 screened women at first round screening | $ 52,053 (¥ 364,371) | $ 50,422 (¥ 352,954) | / |
 Cost per 1000 screened women at 1-year follow-up | $ 4940 (¥ 34,580) | $ 6480 (¥ 45,360) | / |
 Total cost per 1000 screened women per round | $ 56,993 (¥ 398,951) | $ 56,902 (¥ 398,314) | / |
 Cost per each identified CIN2+ women per round | $ 1654 (¥ 11,578) | $ 1867 (¥ 13,069) | / |